Biotechnology company Stämm, focused on simplifying and scaling biomanufacturing, has raised $17.0M in Series A funding. The capital infusion will advance Stämm's development of accessible, plug-and-play manufacturing solutions, designed to automate and optimize the continuous production of biologics and cell therapies. These innovations aim to make biomanufacturing more sustainable and repeatable.















.png&w=3840&q=75)


